PSC833, cyclosporinA, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts

Biochemical and Biophysical Research Communications

Volumn 257, Issue 2, 1999, Pages 410-413

  Wigler, Paul W ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCEIN; CYCLOSPORIN A; DEXNIGULDIPINE; VALSPODAR; CALCEIN AM; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE; FLUORESCEIN DERIVATIVE; GLYCOPROTEIN P; NIGULDIPINE;

ARTICLE; HUMAN; HUMAN CELL; LYMPHOBLAST; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; HALF LIFE TIME; IC 50; KINETICS; LEUKEMIA; LYMPHOCYTE; METABOLISM; MOLECULAR WEIGHT; PATHOLOGY;

CYCLOSPORINE; CYCLOSPORINS; DIHYDROPYRIDINES; DRUG RESISTANCE, NEOPLASM; FLUORESCEINS; HALF-LIFE; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LEUKEMIA; LYMPHOCYTES; MOLECULAR WEIGHT; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0033551037     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.1999.0475     Document Type: Article

References (19)

1. Marshall N. J., Piddock L. J. V. Microbiología. 13:1997;285-300.
2. Sandor V., Wilson W., Fojo T., Bates S. E. Leuk. Lymphoma. 28:1997;23-31.
3. Ferry D. R. Int. J. Clin. Pharmacol. Ther. 36:1998;29-40.
4. Holló Z., Homolya L., Davis C. W., Sarkadi B. Biochim. Biophys. Acta. 1191:1994;384-388.
5. Liminga G., Nygren P., Larsson R. Exp. Cell. Res. 212:1994;291-296.
6. Wigler P. W., Patterson F. K. Biochim. Biophys. Acta. 1189:1994;1-6.
7. Keller R. P., Altermatt H. J., Nooter K., Poschmann G., Laissue J. A., Bollinger P., Hiestand P. C. Int. J. Cancer. 50:1992;593-597.
8. Wigler P. W., Lyon K. L., Patterson F. K., La Loggia A. J., Diaz-Araúzo H., Reddy M. S., Cook J. M. Mol. Pharmacol. 46:1994;563-567.
9. Wigler P. W. J. Bioenerg. Biomembr. 28:1996;279-284.
10. Webb, J. L. 1963, in, 1, 68, Academic Press, NY.
11. Boer R., Haas S., Schödl A. Eur. J. Cancer. 30A:1994;1117-1123.
12. Archinal-Mattheis A., Rzepka R. W., Watanabe T., Kokubu N., Itoh Y., Combates N. J., Bair K. W., Cohen D. Oncol. Res. 7:1995;603-610.
13. Tiberghien F., Loor F. Anticancer Drugs. 7:1996;568-578.
14. Essodaïgui M., Broxterman H. J., Garnier-Suillerot A. Biochemistry. 37:1998;2243-2250.
15. Homolya L., Holló Z., Germann U. A., Pastan I., Gottesman M. M., Sarkadi B. J. Biol. Chem. 268:1993;21493-21496.
16. Cheng Y., Prusoff W. H. Biochem. Pharmacol. 22:1973;3099-3108.
17. Ayesh S., Shao Y. M., Stein W. D. Biochim. Biophys. Acta. 1316:1996;8-18.
18. Spoelstra E. C., Westerhoff H. V., Dekker H., Lankelma J. Eur. J. Biochem. 207:1992;567-579.
19. Shapiro A. B., Ling V. Eur. J. Biochem. 250:1997;130-137.